{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-020010","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.585966+00:00","generated_at":"2026-06-02T23:58:24.642318+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cardiff Oncology Q1 2024: $67.2M cash, ONSEMBLE data show 50% ORR in bev naïve mCRC","bullets":["Cash and equivalents $67.2M as of March 31, 2024; projected runway into Q3 2025.","Operating expenses $11.1M, down $1.0M YoY; net cash used in ops $7.7M.","ONSEMBLE trial: bev naïve patients on onvansertib+SoC had 50% ORR vs 0% for SoC alone.","Initial readout from first-line RAS-mutated mCRC Phase 2 CRDF-004 trial expected 2H 2024.","Preclinical AACR data showed onvansertib activity in RAS wild-type mCRC, SCLC, and ovarian cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-020010","json":"https://secwatch.observer/filing/0001628280-24-020010.json","markdown":"https://secwatch.observer/filing/0001628280-24-020010.md","text":"https://secwatch.observer/filing/0001628280-24-020010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024020010/0001628280-24-020010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024020010/crdf-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:58:24.642318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a59fb015e39b8086ee20b669c5f7f7e1a085daf0","claim":"Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 2, 2024, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2024 .","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024020010/0001628280-24-020010-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}